EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preemptive Rituximab for Epstein–Barr Virus Reactivation After Hematopoietic Cell Transplantation: Necessary for All?

Anna Beatriz Coelho de Souza, Anderson João Simione, Ana Cláudia Ferrari Dos Santos, Iago Colturato, Fernanda Rodrigues Barbieri, Juliana Ribeiro do Prado Moreno, Lilian Perílio Zanetti, Leila Cibele Serra de Oliveira, Erika Rodrigues Pontes Delattre, Juliana Silva Santos, Mair Pedro de Souza, Vergílio A R Colturato und 1 weitere

Transplant Infectious Disease · 2026

DOI: 10.1111/tid.70124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2026. Verfasst von Anna Beatriz Coelho de Souza und 12 weiteren Autor:innen. Beteiligte Einrichtung: HCT Program, Fundação Hospital Amaral Carvalho, Jaú, Brazil. Hauptthemen laut MEDLINE: Rituximab, Epstein-Barr Virus Infections, Hematopoietic Stem Cell Transplantation, Virus Activation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In allogeneic HCT recipients, risk factors for PTLD and EBV end‐organ diseases are well established. Therefore, weekly monitoring of EBV reactivation with quantitative PCR is indicated for patients at risk. Although based on uncontrolled studies and supported by moderate strength of evidence, preemptive rituximab has been recommended in cases of EBV reactivation, without a clearly defined EBV DNAemia threshold. Rituximab is known to be associated with prolonged B‐cell depletion and secondary hypogammaglobulinemia, resulting in an increased risk of infectious complications and poor vaccine responses for an extended period.

Methods

In this retrospective single‐center study, we evaluated the safety and effectiveness of immunosuppression (IS) reduction as the first approach in EBV reactivation in 328 HCT recipients, limiting the introduction of rituximab to patients who did not respond to IS reduction or who developed EBV end‐organ disease or PTLD.

Results

During follow‐up, 178 patients experienced EBV reactivation, with a cumulative incidence of 54.6%. Among these, four patients developed EBV encephalitis (2.2%), and no cases of PTLD were identified. Rituximab was administered to only 12 patients (6.7%). In multivariate analysis, EBV reactivation was significantly associated with chronic GVHD, which may be related to EBV reactivation itself, rapid IS withdrawal, or both. EBV reactivation did not adversely affect non‐relapse mortality or overall survival in this cohort.

Conclusion

IS reduction as the first‐line approach to EBV reactivation was safe and effective in most patients with increasing EBV DNAemia. Consequently, rituximab was required in fewer than 10% of cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabEpstein-Barr Virus InfectionsHematopoietic Stem Cell TransplantationVirus ActivationHerpesvirus 4, HumanHumansRetrospective StudiesMaleFemaleAdultMiddle AgedYoung AdultAdolescentAgedChildGraft vs Host DiseaseLymphoproliferative DisordersChild, PreschoolRisk FactorsTransplantation, Homologous

Stichwörter der Autor:innen

EBVHCTPTLDend‐organ diseaseimmunosuppressionrituximab

Substanzen

Rituximab

Autor:innen und Institutionen

  • HCT Program, Fundação Hospital Amaral Carvalho, Jaú, Brazil.
  • Virology Laboratory, Institute of Tropical Medicine, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Zitieren

APA

de Souza, A. B. C., Simione, A. J., Dos Santos, A. C. F., Colturato, I., Barbieri, F. R., do Prado Moreno, J. R., Zanetti, L. P., de Oliveira, L. C. S., Delattre, E. R. P., Santos, J. S., de Souza, M. P., Colturato, V. A. R., & Machado, C. M. (2026). Preemptive Rituximab for Epstein–Barr Virus Reactivation After Hematopoietic Cell Transplantation: Necessary for All?. Transplant Infectious Disease. https://doi.org/10.1111/tid.70124

Vancouver

de Souza ABC, Simione AJ, Dos Santos ACF, Colturato I, Barbieri FR, do Prado Moreno JR, et al. Preemptive Rituximab for Epstein–Barr Virus Reactivation After Hematopoietic Cell Transplantation: Necessary for All?. Transplant Infectious Disease. 2026. doi:10.1111/tid.70124

BibTeX
@article{deSouza2026,
  author = {de Souza, Anna Beatriz Coelho and Simione, Anderson João and Dos Santos, Ana Cláudia Ferrari and Colturato, Iago and Barbieri, Fernanda Rodrigues and do Prado Moreno, Juliana Ribeiro and Zanetti, Lilian Perílio and de Oliveira, Leila Cibele Serra and Delattre, Erika Rodrigues Pontes and Santos, Juliana Silva and de Souza, Mair Pedro and Colturato, Vergílio A R and Machado, Clarisse M},
  title = {Preemptive Rituximab for Epstein–Barr Virus Reactivation After Hematopoietic Cell Transplantation: Necessary for All?},
  journal = {Transplant Infectious Disease},
  year = {2026},
  doi = {10.1111/tid.70124}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche